Open Access

YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies

  • Marta Querol-Vilaseca1, 2,
  • Martí Colom-Cadena1, 2,
  • Jordi Pegueroles1, 2,
  • Carla San Martín-Paniello1,
  • Jordi Clarimon1, 2,
  • Olivia Belbin1, 2,
  • Juan Fortea1, 2 and
  • Alberto Lleó1, 2Email author
Journal of Neuroinflammation201714:118

DOI: 10.1186/s12974-017-0893-7

Received: 15 May 2017

Accepted: 2 June 2017

Published: 9 June 2017

Abstract

Background

The innate immune system is known to be involved early in the pathogenesis of Alzheimer’s disease (AD) and other neurodegenerative disorders. The inflammatory response in the central nervous system can be measured postmortem or through a series of inflammatory mediator surrogates. YKL-40 (also named Chitinase-3-like I) has been frequently investigated in body fluids as a surrogate marker of neuroinflammation in AD and other neurological disorders. However, the expression pattern of YKL-40 in the human brain with neurodegenerative pathology remains poorly investigated. Our aim was to study the cellular expression pattern of YKL-40 in the brain of patients with clinical and neuropathological criteria for AD (n = 11); three non-AD tauopathies: Pick’s disease (PiD; n = 8), corticobasal degeneration (CBD; n = 8) and progressive supranuclear palsy (PSP; n = 9) and a group of neurologically healthy controls (n = 6).

Methods

Semiquantitative neuropathological evaluation and quantitative confocal triple immunofluorescence studies were performed. An in-house algorithm was used to detect and quantify pathology burden of random regions of interest on a full tissue-section scan. Kruskal-Wallis and Dunn’s multiple comparison tests were performed for colocalization and quantification analyses.

Results

We found that brain YKL-40 immunoreactivity was observed in a subset of astrocytes in all four diseases and in controls. There was a strong colocalization between YKL-40 and the astroglial marker GFAP but not with neuronal nor microglial markers. Intriguingly, YKL-40-positive astrocytes were tau-negative in PSP, CBD and PiD. The number of YKL-40-positive astrocytes was increased in tauopathies compared with that in controls. A positive correlation was found between YKL-40 and tau immunoreactivities.

Conclusions

This study confirms that YKL-40 is expressed by a subset of astrocytes in AD and other tauopathies. YKL-40 expression is elevated in several neurodegenerative conditions and correlates with tau pathology.

Keywords

YKL-40 Alzheimer’s disease Tauopathies Tau Astrocytes Neuroinflammation

Background

There is growing evidence that the immune system is involved early in the pathogenesis of Alzheimer’s disease (AD) and in other neurodegenerative diseases [1, 2]. The activation of the immune system in AD (often referred to as “neuroinflammation”) is known to be present at all stages of AD and is believed to play an active role in the disease process. The activation of microglia and astrocytes as a reaction to ongoing deposition of Aβ triggers the production of several proinflammatory signal molecules including cytokines, chemokines, complement molecules, growth factors and cell adhesion molecules [3]. The recent association of gene encoding inflammatory proteins, such as TREM2 and CD33 with AD [46], has further supported the role of the innate immune response in the aetiology and progression of AD. In addition, the increased feasibility of measuring a wide range of inflammatory molecules in biofluids from patients at different AD stages has expanded our understanding about the type of immune responses observed in neurodegenerative diseases. A variety of cytokines, chemokines and other inflammatory mediators are increased in cerebrospinal fluid (CSF) or in plasma in AD [1]. One of the proteins that has been frequently measured in body fluids as a surrogate marker of neuroinflammation in AD and other neurological disorders is YKL-40 (also named Chitinase 3-like I) [7, 8]. It has been described that YKL-40 participates in connective tissue cell growth, endothelial cell migration and inhibition of mammary epithelial cell differentiation and promotes tumour angiogenesis [9]. However, its biological and physiological functions in the central nervous system remain unclear. YKL-40 is increased in the CSF of multiple sclerosis (MS) patients, and YKL-40 levels correlate well with disease progression [10]. In previous studies, we and others [11, 12] found elevated YKL-40 levels in the CSF of AD patients. Interestingly, increased levels of YKL-40 were found in the preclinical stages of AD [13, 14] indicating that the immune system activation occurs early in the disease. These studies have also shown that CSF levels of YKL-40 and tau strongly correlate [11, 12]. Additional studies have indicated that YKL-40 is also elevated in the CSF of patients with other tauopathies, such as frontotemporal dementia (FTD), corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) [11, 13, 15, 16].

Despite the wide use of YKL-40 as a biochemical marker in neurodegenerative diseases, its distribution and pattern of expression in the human brain remains unclear. A recent study found that expression levels of chitinase genes in the brain regions of late onset AD (LOAD) patients are increased compared with healthy controls [17], but the cellular source of expression of these proteins remains uncertain. Some studies have suggested that YKL-40 is expressed in astrocytes in a variety of acute neuroinflammatory conditions, such as traumatic brain injury or multiple sclerosis [18, 19]. Other studies, however, support the idea that YKL-40 is also expressed in macrophage/microglia cell types in these conditions [19, 20]. In AD, studies show a variable pattern of YKL-40 expression that includes astrocytes, microglia or, on rare occasions, neurons [12, 21, 22]. The aim of the present work was to determine the cellular pattern of YKL-40 expression in the human brain tissue in AD and other tauopathies. We also investigated the relationship between YKL-40 expression and tau aggregates in these disorders.

Methods

Standard protocol approval and patient consent

A written informed consent was given by all donors and/or next of kin for the use of brain tissue for research. This study was approved by the local ethics committee at Hospital de Sant Pau, Barcelona, Spain.

Human brain samples

Human brain samples were provided by the Neurological Tissue Bank (NTB) of the Biobanc-Hospital Clínic-IDIBAPS and processed as previously described [23] and as internationally recommended [24]. The initial study group consisted of 40 patients who met clinical and neuropathological criteria for AD (n = 11), PSP (n = 10), CBD (n = 9), Pick’s disease (PiD; n = 10) and a group of healthy controls (n = 7).

Neuropathologic assessment

We assessed formalin-fixed and paraffin-embedded tissue blocks from frontal cortex Brodmann areas 8/9. Immunohistochemistry was performed on 5-μm-thick sections on an automated stainer (DAKO Autostainer Plus; DAKO, Glostrup, Denmark) using the following primary antibodies: anti-amyloid β (clone 6F/3D, dilution 1:400; DAKO) and anti-phosphorylated tau (clone AT8, dilution 1:2000; Thermo Scientific, Waltham, MA). Reaction was visualized by the EnVision+ system peroxidase procedure (DAKO).

Immunoreactive structures of AT8 (NFTs, NTs, pretangles, dystrophic neurites, balloon cells, Pick bodies, ramified astrocytes, astrocytic plaques, tufted astrocytes and coiled bodies) and β-amyloid (mature, primitive and diffuse plaques) were systematically assessed in all cases. Neurofibrillary pathology was staged according to Braak criteria [25, 26]. β-amyloid phases were evaluated according to Thal criteria [27]. The National Institute on Aging-Alzheimer’s Association Guidelines for neuropathologic assessment of AD was also applied [24]. Healthy controls without tau or amyloid pathology were included. Neuropathologic evaluation was carried out by three investigators on a multiheaded microscope.

Immunohistochemistry (IHC) and immunofluorescence (IF)

Formalin-fixed and paraffin-embedded brain sections of frontal cortex were dewaxed and pretreated with Tris/EDTA buffer pH 9 at high temperature. The following primary antibodies were incubated overnight at 4 °C: polyclonal goat anti-YKL-40 (R&D Systems, AF2599, dilution 1:200), rabbit anti-GFAP (Sigma, G9269, dilution 1:500), phosphorylated tau clone AT8 (Thermo Scientific, MN1020, dilution 1:1000), monoclonal mouse anti-MAP2 (Sigma, M4403, dilution 1:500) and rabbit anti-Iba-1 (Wako Chemicals, 019-19741, 1:500). For IHC, the endogenous peroxidase activity was blocked, sections were HRP-labelled (Dako, Glostrup, Denmark, dilution 1:200) and the reaction was visualized by the EnVision+ system peroxidase procedure (DAKO, Glostrup, Denmark). For IF, sections were incubated for 1 h with Alexa Fluor 488, 555 or 647 (Invitrogen, Carlsbad, CA, USA, dilution 1:1000) secondary antibodies and stained with Sudan black B (Merck, Whitehouse Station, NJ, USA) to mask tissue autofluorescence. Nuclei were stained with Hoechst 33258 (Life Technologies, Carlsbad, CA, USA, dilution 1:1000), and coverslips were added with Immu-Mount (Fisher Scientific, Rockford, USA) mounting medium.

Image acquisition and analysis

Fluorescence images were acquired with a Leica inverted fluorescent confocal microscope (Leica TCD SP5-AOBS, Wetzlar, Germany) with a ×40 1.4 NA oil objective. Alexa Fluor 488, 555 and 647 were sequentially excited with 488-, 561- and 633-nm laser lines and captured with a spectral window of 498 to 530, 571 to 620 and 645 to 720 nm, respectively. A pulsed 405-nm laser was used for Hoechst visualization capturing images in a spectral range of 415 to 475 nm. Sections without antibodies or with secondary antibodies only were imaged to ensure specific and independent fluorophore visualization. For each case, at least 10 images per area were acquired. Pictures were taken in 4–5 z planes with a 0.7-μm pinhole. Maximal intensity projection of each type of aggregate was used for figure visualization.

For colocalization analyses, images were acquired avoiding saturated pixels. Saturation was only minimally applied for presentation purposes in the figure. Protein colocalization was evaluated using FIJI imaging software [28]. All images were analyzed following the same semi-automated in-house algorithm. Briefly, for each channel, the lowest intensity signals within a z-stack were removed to minimize background. An automated threshold was then estimated to create binary images. To quantify the overlap between proteins, Manders’ colocalization coefficient was calculated for each channel [29, 30].

For quantification analysis of IHC stains, full-section scans were obtained with Pannoramic MIDI II (3DHistech, Budapest, Hungary). Cortical grey matter of each case was delimited blinded to clinical phenotypes. An in-house computer-based algorithm was developed to quantify tau pathology burden and GFAP immunoreactivity with MATLAB R2015b software (The MathWorks, Inc., Natick, MA, USA) (Additional file 1: Figure S1). Briefly, the algorithm allows defining random regions of interest (ROIs) on a full-section scan, to compute densities of protein expression and to quantify the number of immunoreactive objects. This procedure was adapted from a published digital image analysis [31]. An outlier test was performed, and cases reported as statistical outliers were removed from the analysis. Five cases were excluded such that the final sample included the following cases: 11 AD, 9 PSP, 8 CBD, 8 PiD and 6 healthy controls. All quantitative analyses performed with the developed semi-automated method were manually validated in a subset of images. YKL-40-positive objects were manually validated by two investigators in order to ensure the correct identification of immunoreactivity patterns by the automated algorithm. Both investigators were blinded to clinical phenotypes.

Statistical analysis

Kruskal-Wallis and Dunn’s multiple comparison tests were performed for colocalization and quantification analyses. Correlation between proteins was measured by the Spearman coefficient. Statistical significance was set at 5% (α = 0.05). All data were analyzed using the GraphPad Prism 6.0 software (GraphPad Software, Inc., CA, USA).

Results

YKL-40 is expressed by astrocytes in human brain tissue

We first examined the cellular expression of YKL-40 in human brain tissue from an AD patient and a healthy control. Using a double immunofluorescence technique, we investigated the colocalization between YKL-40 and three different markers: MAP2 as a neuronal marker, GFAP as an astroglial marker and IBA-1 as a microglial marker (Fig. 1). In both the AD and control brains, we found that YKL-40 colocalized in some cells labelled with the astrocytic marker GFAP, with a perinuclear cytoplasmic pattern extending to some proximal astroglial processes (Fig. 1a–h). Conversely, there was no colocalization between YKL-40 and the neuronal marker, MAP2, or with the microglia marker, IBA-1 (Fig. 1i–x). These findings indicate that YKL-40 is expressed by astrocytes in the frontal cortex of healthy and diseased human brain tissue.
Fig. 1

YKL-40 expression pattern in human brain tissue from an AD patient and a healthy control. Representative images of double immunofluorescence performed with YKL-40 (red) and three different cellular markers, GFAP (astroglial, green), MAP2 (neuronal, green) and IBA-1 (microglial, green). Nuclei are marked in blue. ah YKL-40 immunoreactivity was detected in the cytoplasm of GFAP+ cells (asterisk), indicating an astroglial origin. ip No colocalization was observed between YKL-40 and the neuronal marker, MAP2 or (qx) with the microglial marker, IBA-1. Scale bar = 20 μm

YKL-40 is expressed in a subset of astrocytes in AD and other non-AD tauopathies

We next investigated whether the pattern of YKL-40 was similar between AD and other neurodegenerative diseases. YKL-40 expression pattern was examined in the frontal cortex from patients with different forms of frontotemporal lobar degeneration (FTLD) such as PiD, CBD and PSP. Since tau is known to aggregate in astrocytes in these subtypes of FTLD [32], we explored the relationship between YKL-40 expression and the different forms of tau aggregates in these conditions.

We performed triple immunofluorescence studies with antibodies against YKL-40, GFAP and tau in different cases of AD and non-AD tauopathies (n = 40) (Fig. 2). We confirmed that 75–85% of YKL-40 immunoreactivity colocalized with GFAP indicating an astroglial origin in cases with AD, PiD, CBD and PSP (Fig. 2u). The immunoreactivity of YKL-40 was mainly cytoplasmic while GFAP immunoreactivity extended distally to astrocytic processes and plasma membrane, which explains the lack of complete overlap. No differences in the expression pattern of YKL-40 between the AD and FTLD cases were found (all p > 0.05). Interestingly, in PSP, CBD and PiD, where tau-positive astrocytes are commonly found, most YKL-40-positive astrocytes were tau negative and vice versa. Accordingly, colocalization between YKL-40 and tau was negligible (<7%). On the other hand, as previously described [32], substantial overlap between tau and GFAP immunoreactivity was found in PiD (~37%), CBD (~37%) and PSP (~51%), whereas no overlap was found in AD. The distribution of YKL-40-positive astrocytes was mainly isolated but occasionally found surrounding blood vessels. These data support the idea that the immunoreactivity patterns of astroglial YKL-40 and tau are spatially distinct in non-AD tauopathies.
Fig. 2

YKL-40 immunoreactivity pattern and colocalization analyses in different tauopathies. Representative images of the triple immunofluorescence studies performed with YKL-40 (red), GFAP (green) and tau (magenta) antibodies. Nuclei are marked in blue. All four tauopathies investigated, ae AD, fj PiD, ko CBD and pt PSP, showed a cytoplasmic astroglial expression pattern of YKL-40. Scale bar = 20 μm. u Colocalization analysis confirmed that approximately 80% of YKL-40 colocalized with GFAP in all tauopathies. No colocalization was detected between YKL-40 and tau in any condition. As expected, non-AD tauopathies showed an overlap between tau and GFAP. ***p < 0.001; *p < 0.05

Relationship between YKL-40 expression, tau pathology and astrogliosis

We next investigated the differences in total YKL-40 immunoreactivity between the neurodegenerative conditions and healthy control brains. Immunohistochemistry for YKL-40, GFAP and tau was performed on three consecutive sections from the frontal cortex from each case, respectively. Full-section scans of all samples were obtained, and quantification of tau, YKL-40 and GFAP was performed. Representative images of YKL-40, tau and GFAP immunoreactivity are shown in Fig. 3(a–o). A similar YKL-40 expression pattern was observed across all neurodegenerative conditions although expected differences in tau deposits were detected between conditions.
Fig. 3

Quantification of YKL-40, tau pathology burden and astrogliosis in different tauopathies. ao Representative images of YKL-40, tau and GFAP immunoreactivity of controls and the four tauopathies under study. ae YKL-40 expression pattern. fj Main tau deposits and aggregates of each condition. ko Astrogliosis among the tauopathies and controls. Scale bar = 20 μm. p YKL-40 immunoreactivity (objects/μm2) measured in all conditions. qs Correlation between different markers. Levels of YKL-40 and GFAP correlated positively with tau aggregation. Solid lines indicate the linear regression, and dotted lines indicate 95% CI. RS, Spearman rho coefficient.

We next applied our in-house semi-automated algorithm to quantify total immunoreactivity (density/μm2) and number of objects of Tau and GFAP markers (Additional file 1: Figure S1). YKL-40 levels were increased in all neurodegenerative diseases (except PiD) compared with controls (p < 0.05). No differences were observed between the different tauopathies (Fig. 3p). Less than 10% of GFAP-positive astrocytes expressed YKL-40 (10% in PSP, 7% in CBD, 5% in AD, 4% in PiD and 1% in healthy controls).

We next examined the correlation between YKL-40, tau and GFAP markers. We found a positive correlation between tau pathology burden scores and YKL-40 (n = 36; r = 0.447; p = 0.006) (Fig. 3q) and between GFAP and tau pathology (n = 36; r = 0.651; p < 0.0001) (Fig. 3s). However, we did not detect a correlation between YKL-40 and GFAP (n = 36; p = 0.776) scores (Fig. 3r).

Discussion

In the present study, we found that YKL-40 is expressed by astrocytes in human brain tissue in healthy controls and in different neurodegenerative diseases. The immunoreactivity pattern of YKL-40 was mainly cytoplasmic extending to proximal astrocytic processes. We also observed that this protein is expressed in a subset of astrocytes (<10%) that do not contain tau aggregates in non-AD tauopathies.

To date, the pattern of expression of YKL-40 in the central nervous system has remained controversial and has not been fully elucidated. Some studies have described that YKL-40 is expressed in microglia [33, 34] while others have found it in astrocytes [12, 35]. These discrepancies may be because YKL-40 expression seems to vary depending on the disease and the severity of the neuroinflammatory response [19, 35]. It has been shown that in multiple sclerosis, YKL-40 is expressed by macrophages/microglial cells (CD68+) in low and high inflammatory activity lesions [19]. However, YKL-40 expression was also expressed in the cytoplasm of astrocytes (GFAP+) in high inflammatory activity lesions [19]. Another study reported that in human brain infarction, YKL-40 astrocytic expression depends on the stage of underlying inflammation, increasing during the acute inflammation phase and diminishing as the inflammation resolves [35]. Moreover, it has been shown by others that YKL-40 is also expressed by peripheral cells including chondrocytes [36], synoviocytes [37], vascular smooth muscle cells [38], macrophages [39] and neutrophils [40]. For example, it has been reported that expression of YKL-40 in breast cancer tissue correlates with tumour grade [41] and that YKL-40 macrophage expression is upregulated in patients with chronic obstructive pulmonary disease and correlates with its severity [42]. In vitro studies have shown a dramatically increase of YKL-40 expression during astrocyte differentiation [43]. Other studies based on immunohistochemical techniques suggested that YKL-40 together with SSEA-4 marker expression represent an unexplored astrogenic lineage [44]. Here, we have confirmed that YKL-40 shows an astroglial cytoplasmic immunoreactivity pattern in postmortem human frontal cortex from healthy controls and AD patients. We did not detect YKL-40 expression in microglia or in neurons.

We also found YKL-40 in the cytoplasm of astrocytes in non-AD tauopathies, including PiD, CBD and PSP. Although YKL-40 was typically found in isolated astrocytes, we occasionally observed focal astrocytic YKL-40 immunoreactivity around blood vessels. Previous studies have suggested that YKL-40 transcription is induced in astrocytes by proinflammatory factors released from macrophages [21]. One possible explanation for this observation is that perivascular macrophages may induce YKL-40 expression in astrocytes that are in close proximity. The colocalization between YKL-40 and GFAP was around 80% indicating that GFAP immunoreactivity, typically extending towards the astrocyte membrane and processes, surrounds that of YKL-40. Interestingly, YKL-40 immmunoreactivity was independent of tau, indicating that in non-AD tauopathies, YKL-40 is expressed in a tau-negative subset of astrocytes. Whether YKL-40 could be a compensatory response to inhibit tau aggregation or, on the contrary, represents an initial event that facilities tau deposition requires further investigation. As expected, colocalization between tau and GFAP was found in non-AD tauopathies reflecting the distinctive glial tau aggregation in these disorders [32]. The 15% overlap observed in AD may be explained by neuropil threads crossing astrocyte processes in close proximity that are measured as colocalization due to the resolution limits.

Recent studies have demonstrated that YKL-40 levels are increased in the CSF of patients with AD and FTD compared with those in the healthy controls [1116, 45, 46]. In addition, a positive correlation between YKL-40, total tau and p-tau has been reported in CSF, suggesting that inflammation and tau-associated neurodegeneration are related pathophysiological processes. In agreement, animal models and co-culture studies have shown that activated glia-induced neuronal tau phosphorylation and aggregation [47]. In postmortem brains, our semi-automated method revealed that total YKL-40 levels were statistically increased in all tauopathies (except PiD) compared with healthy controls. These results are in agreement with studies that investigated YKL-40 levels in CSF of AD and FTD patients [1116, 45, 46]. It is important to note that only a limited proportion of astrocytes (always less than 10%) expressed YKL-40 in human frontal cortex. Interestingly, we found a positive correlation between YKL-40 and tau pathology burden (r = 0.447) suggesting that inflammation and neurodegeneration may be closely related processes in humans. The lack of correlation between YKL-40 and GFAP together with the positive correlation between tau and GFAP (r = 0.651) in our study also may indicate that YKL-40 expression is independent of astrocyte activation in neurodegenerative disease.

Conclusions

In conclusion, this is, to our knowledge, the first detailed neuropathologic characterization of YKL-40 expression in human brain tissue. Moreover, the study includes tissue samples from healthy controls and four neurodegenerative diseases. Combining confocal microscopy and the application of a semi-automated method to quantify pathology burden, we have shown that the immunoreactivity pattern of YKL-40 in AD and other tauopathies is astroglial. YKL-40 is expressed by a subset of astrocytes that do not contain tau aggregates in non-AD tauopathies. Finally, we have found that YKL-40 inflammatory marker is associated with tau pathology in neurodegenerative diseases that accumulate tau.

Abbreviations

AD: 

Alzheimer’s disease

CBD: 

Corticobasal degeneration

CSF: 

Cerebrospinal fluid

FTD: 

Frontotemporal dementia

FTLD: 

Frontotemporal lobar degeneration

GFAP: 

Glial fibrillary acidic protein

HRP: 

Horseradish peroxidase

Iba-1: 

Ionized calcium-binding adapter molecule 1

IF: 

Immunofluorescence

IHC: 

Immunohistochemistry

LOAD: 

Late onset Alzheimer’s disease

MAP2: 

Microtubule-associated protein 2

MS: 

Multiple sclerosis

NFT: 

Neurofibrillary tangles

NT: 

Neuropil threads

NTB: 

Neurological Tissue Bank

PiD: 

Pick’s disease

PSP: 

Progressive supranuclear palsy

ROI: 

Regions of interest

TREM2: 

Triggering receptor expressed on myeloid cells 2

Declarations

Acknowledgements

The authors thank Ellen Gelpi for the neuropathological review of the cases and Eva Companys for the confocal microscopy assistance.

Funding

The funding of this study was from Fondo de Investigación Sanitario, Instituto de Salud Carlos III (PI14/1561 to A.L.).

Availability of data and materials

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Authors’ contributions

MQ-V, MC-C and AL contributed to the conception and design. MQ-V, MC-C, JP, JC, OB, JF and AL contributed to the acquisition and analysis or interpretation of data. MQ-V, MC-C, OB, and AL did the drafting/revision of the article. MQ-V, MC-C, JP, JC, OB, JF, and AL contributed to the final approval of the version to be published. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable

Ethics approval and consent to participate

A written informed consent was given by all donors and/or next of kin for the use of brain tissue for research. This study was approved by the local ethics committee at Hospital de Sant Pau, Barcelona, Spain.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau - Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona
(2)
Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED)

References

  1. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16:358-72.Google Scholar
  2. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388-405.Google Scholar
  3. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer’s disease, role of cytokines. Sci World J. 2012;2012:756357.Google Scholar
  4. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–27.View ArticlePubMedGoogle Scholar
  5. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368:107–16.View ArticlePubMedGoogle Scholar
  6. Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16:848–50.PubMedPubMed CentralGoogle Scholar
  7. Perrin RJ, Craig‐Schapiro R, Malone JP, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer’s disease. PLoS One. 2011;6, e16032.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer’s disease. Biomark Med. 2012;6:455–76.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol. 2013;4:122.Google Scholar
  10. Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010;133:1082–93.View ArticlePubMedGoogle Scholar
  11. Alcolea D, Carmona-Iragui M, Suarez-Calvet M, Sanchez-Saudinos MB, Sala I, Anton-Aguirre S. Relationship between ß-secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers Dis. 2014;42:157–67.PubMedGoogle Scholar
  12. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry. 2010;68(10):903–12.Google Scholar
  13. Alcolea D, Martínez-Lage P, Sánchez-Juan P, Olazarán J, Antúnez C, Izagirre A, Ecay-Torres M, Estanga A, Clerigué M, Guisasola MC, Sánchez Ruiz D, Marín Muñoz J, Calero M, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology. 2015;85:626–33.View ArticlePubMedGoogle Scholar
  14. Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, Balasa M, Sánchez-Valle R, Molinuevo JL. Cerebrospinal fluid Level of YKL-40 protein in preclinical and prodromal Alzheimer’s disease. J Alzheimer’s Dis. 2014;42:901–8.Google Scholar
  15. Teunissen CE, Elias N, Koel-Simmelink MJA, et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimers Dement (Amst). 2016;2:86–94.Google Scholar
  16. Alcolea D, Vilaplana E, Suarez-Calvet M, Illán-Gala I, Blesa R, Clarimón J, et al. Cerebrospinal fluid sAPPβ, YKL-40 and neurofilament light in frontotemporal lobar degeneration. Neurology. 2017 (in press).Google Scholar
  17. Sanfilippo C, Malaguarnera L, Di Rosa M. Chitinase expression in Alzheimer’s disease and non-demented brains regions. J Neurol Sci. 2016;369:242–9.View ArticlePubMedGoogle Scholar
  18. Bonneh‐Barkay D, Zagadailov P, Zou H, et al. YKL‐40 expression in traumatic brain injury: an initial analysis. J Neurotrauma. 2010;27:1215–23.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-Martín E, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015;138:918–31.Google Scholar
  20. Hinsinger G, Galéotti N, Nabholz N, Urbach S, Rigau V, Demattei C, Lehmann S, Camu W, Labauge P, Castelnovo G, et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler. 2015;21:1251–61.Google Scholar
  21. Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012;22:530–46.View ArticlePubMedGoogle Scholar
  22. Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Mansson JE, Johansson JO, Olsson B, Wallin A, Svensson J, et al. Cerebrospinal fluid microglial markers in Alzheimer’s disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med. 2011;13(2):151–9. Google Scholar
  23. Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Martí MJ, Clarimón J, Lleó A. Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol. 2013;72:1203–12.Google Scholar
  24. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol. 2012;123(1):1–11.Google Scholar
  25. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389–404.Google Scholar
  26. Alafuzoff I, Pikkarainen M, Al-Sarraj S, et al. Interlaboratory comparison of assessments of Alzheimer disease-related lesions: a study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2006;65:740–57.View ArticlePubMedGoogle Scholar
  27. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791–800.View ArticlePubMedGoogle Scholar
  28. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–82.Google Scholar
  29. Manders EMM, Verbeek FJ, Aten JA. Measurement of colocalization of objects in dual-colour confocal images. J Microscopy. 1993;169:375–82.View ArticleGoogle Scholar
  30. Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol. 2011;300:C723–42.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Irwin DJ, Byrne MD, McMillan CT, Cooper F, Arnold SE, Lee EB, Van Deerlin VM, Xie SX, Lee VM, Grossman M, Trojanowski JQ. Semi-automated digital image analysis of Pick’s disease and TDP-43 proteinopathy. J Histochem Cytochem. 2016;64(1):54–66.Google Scholar
  32. Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol. 2015;41:3–23.Google Scholar
  33. Hellwig K, Kvartsberg H, Portelius E, Andreasson U, Oberstein TJ, Lewczuk P, Blennow K, Kornhuber J, Maler JM, Zetterberg H, Spitzer P. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease. Alzheimers Res Ther. 2015;7(1):74.Google Scholar
  34. Lautner R, Mattsson N, Schöll M, Augutis K, Blennow K, Olsson B, Zetterberg H. Biomarkers for microglial activation in Alzheimer’s disease. Int J Alzheimers Dis. 2011;2011:939426.Google Scholar
  35. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation. 2010;7:34.Google Scholar
  36. Hu B, Trinh K, Figueira WF, Price PA. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J Biol Chem. 1996;271:19415–20.View ArticlePubMedGoogle Scholar
  37. Nyirkos P, Golds EE. Human synovial-cells secrete a 39-kDa protein similar to a bovine mammary protein expressed during the nonlactating period. Biochem J. 1990;269:265–8.Google Scholar
  38. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem. 1995;270:13076–83.Google Scholar
  39. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–5.Google Scholar
  40. Kzhyshkowska J, Gratchev A, Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark Insights. 2007;2:128–46.PubMedPubMed CentralGoogle Scholar
  41. Shao R, Cao QJ, Arenas RB, Bigelow C, Bentley B, Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer. 2011;105(8):1203–9.Google Scholar
  42. Lai T, Wu D, Chen M, Cao C, Jing Z, Huang L, Lv Y, Zhao X, Lv Q, Wang Y, Li D, Wu B, Shen H. YKL-40 expression in chronic obstructive pulmonary disease: relation to acute exacerbations and airway remodeling. Respir Res. 2016;17:31.Google Scholar
  43. Singh SK, Bhardwaj R, Wilczynska KM, Dumur CI, Kordula T. A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40. J Biol Chem. 2011;286:39893–903.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Brøchner CB, Møllgård K. SSEA‐4 and YKL‐40 positive progenitor subtypes in the subventricular zone of developing human neocortex. Glia. 2016;64(1):90–104.Google Scholar
  45. Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol. 2015;3(1):12–20.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Irwin DJ, Trojanowski JQ, Grossman M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer’s disease. Front Aging Neurosci. 2013;5:6.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Arnaud L, Robakis NK, Figueiredo E, Pereira ME. It may take inflammation, phosphorylation and ubiquitination to “tangle” in Alzheimer’s disease. Neurodegener Dis. 2006;3(6):313–9.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement